Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Bayer AG
Deal Size : $28.5 million
Deal Type : Series A Financing
Details : Vesigen’s ARMMs technology enables translation of new modalities such as RNAs and gene-editing complexes into novel treatments for multiple diseases .
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 22, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Bayer AG
Deal Size : $28.5 million
Deal Type : Series A Financing